期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Protective effects of selective and non-selective cyclooxygenase inhibitors in an animal model of chronic stress 被引量:1
1
作者 Anil Kumar beenta kumari Puneet Kumar 《Neuroscience Bulletin》 SCIE CAS CSCD 2010年第1期17-27,共11页
Objective Cyclooxygenase isoenzyme is known to be expressed in different regions of brain, and is mainly used for the treatment of pain and inflammation. Recently, it is proposed that cyclooxygenase isoenzyme may also... Objective Cyclooxygenase isoenzyme is known to be expressed in different regions of brain, and is mainly used for the treatment of pain and inflammation. Recently, it is proposed that cyclooxygenase isoenzyme may also play a key role in the pathophysiology of various brain-related disorders. The present study was aimed to explore the protective effect of cyclooxygenase inhibitors on stress by using an animal model of chronic stress. Methods The animals were forced to swim individually for a period of 6 min every day for 15 d. Then, the behavior (locomotor activity, anxiety and memory) and biochemical (lipid peroxidation, nitrite level, reduced glutathione, and catalase) alterations were assessed. Results Forced swimming for 15 d caused impaired locomotor activity, anxiety-like behavior and decreased percentage of memory retention, as compared to na?ve mice (without chronic fatigue treatment). Biochemical analysis revealed significant increases in lipid peroxidation and nitrite level, while levels of reduced glutathione and catalase activity were both decreased. Chronic treatment with naproxen (14 mg/kg, i.p.), rofecoxib (5 mg/kg, i.p.), meloxicam (5 mg/kg, i.p.), nimesulide (5 mg/kg, i.p.) and valdecoxib (10 mg/kg, i.p.) significantly attenuated these behavioral and biochemical (oxidative damage) alterations in chronic-stressed mice. Conclusion The cyclooxygenase inhibitors could be used in the management of chronic fatigue-like conditions. 展开更多
关键词 chronic fatigue syndrome NAPROXEN VALDECOXIB ROFECOXIB NIMESULIDE MELOXICAM
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部